CMD Dr Krishna Ella, addressing a virtual press conference, said: "We have taken 3-4 strains and studied it. It will come in publication on Medrevix on January 10. In a week's time, our confirmative data would come."
Covaxin, India's indigenous COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) -
India's drug regulator has allowed restricted use of Covaxin in an emergency situation.
While the
The Drug Controller General of India (DCGI) had said that the data available to date showed that Bharat Biotech's Covaxin is "safe" for administration.
During the press conference, Ella hailed the decision of the Indian drug regulator to approve Covaxin for emergency restricted use and termed it as a giant leap for innovation and novel product development in India.
Meanwhile, he lashed out at cynics who raised concerns over the transparency of approval procedures taken to authorise Covaxin, saying that the firm's Covid vaccine candidate is "no way" inferior to Pfizer in terms of transparency.
"People are talking about backlash on Indian companies. That is not done for us. We are the only Indian firm to have published five articles on the Covid-19 vaccine process," Ella claimed.
He also clarified in the conference that he and his family has no involvement with any political party. "Since the politicization over our vaccine has started, I want to clarify that neither I, nor my other family members are involved and working with any political party," Ella stated.